Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome

Brief description of study

This is a study of investigational mesenchymal stromal cells (MSC) for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19. The main purpose of this research is to determine whether MSCs are effective and safe in helping patients with moderate to severe ARDS due to COVID-19 infection. The MSCs used in this study are called remestemcel-L, and these human stem cells are derived from the bone marrow of healthy volunteers and cultured (grown) in a laboratory. This treatment is experimental, meaning that it has not been approved by the Food and Drug Administration (FDA) as a treatment for ARDS. The treatment is being developed by Mesoblast for the treatment of multiple diseases including ARDS due to COVID-19 Infection.


Clinical Study Identifier: s20-00769
ClinicalTrials.gov Identifier: NCT04371393


If you are registered as a volunteer, please login to the dashboard to send referrals.